SPEAR

Vestaron bioinsecticide receives emergency use authorization in Greece for control of devastating tomato leafminer infestations

Retrieved on: 
Wednesday, February 7, 2024

Durham, North Carolina, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vestaron Corporation has been granted an Article 53 Emergency Authorization to provide farmers in Greece with access to a novel bioinsecticide that tackles devastating infestations of tomato leafminer (Tuta absoluta) while presenting minimal risk to beneficials, pollinators, or people.

Key Points: 
  • Durham, North Carolina, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vestaron Corporation has been granted an Article 53 Emergency Authorization to provide farmers in Greece with access to a novel bioinsecticide that tackles devastating infestations of tomato leafminer (Tuta absoluta) while presenting minimal risk to beneficials, pollinators, or people.
  • This authorization in Greece marks a significant commercial milestone for Vestaron and paves the way for its first sales in Europe.
  • Agricultural product distributor Oxygen AgroShield LP petitioned the Greek Ministry of Agriculture for emergency authorization on behalf of 19 other Greek grower groups.
  • Oxygen AgroShield said it was delighted that the temporary authorization had been granted, giving tomato growers the chance to effectively and sustainably control costly tomato leafminer infestations.

Spear Bio, developer of the next-generation ultrasensitive immunodiagnostics and proteomics platform, completes raise of tens of millions of US dollars with oversubscribed Seed Prime

Retrieved on: 
Wednesday, November 29, 2023

The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.

Key Points: 
  • The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.
  • Spear Bio was co-founded in March 2021 as a spin-off from Harvard University's Wyss Institute by Professor Peng Yin and Dr. Feng Xuan.
  • The company is developing the next generation ultrasensitive immunodiagnostics and proteomics platform based on a breakthrough technology its founders developed and licensed from Harvard University: the Successive Proximity Extension Amplification Reaction, or SPEAR.
  • Spear Bio is now focused on bringing to market ultrasensitive immunoassays for areas such as neurology, immunology, and oncology.

Cubic Awarded Royal Australian Air Force (RAAF) Contract to Provide Simplified Planning, Execution, Analysis and Reconstruction (SPEAR) Air Combat Training Solutions

Retrieved on: 
Thursday, June 15, 2023

Cubic Defense was awarded a contract with the Royal Australian Air Force (RAAF) for software licenses and hardware to operate Cubic’s SPEAR software suite.

Key Points: 
  • Cubic Defense was awarded a contract with the Royal Australian Air Force (RAAF) for software licenses and hardware to operate Cubic’s SPEAR software suite.
  • Revolutionizing the world’s most complex and advanced air combat training, SPEAR is the follow-on solution to Cubic’s Individual Combat Aircrew Display System (ICADS), the combat air forces’ live monitor and debrief system for over two decades.
  • View the full release here: https://www.businesswire.com/news/home/20230615556480/en/
    The multi-domain solution innovates air combat training, and the resulting enriched mission data and advanced analytics enable greater debrief fidelity.
  • The multi-domain solution innovates air combat training, and the resulting enriched mission data and advanced analytics enable greater debrief fidelity.

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Retrieved on: 
Monday, March 6, 2023

Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to create a preeminent cell therapy company for solid tumors.

Key Points: 
  • Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to create a preeminent cell therapy company for solid tumors.
  • The combined company will drive forward its pipeline of cell therapies aimed at treating multiple cancers with high unmet medical needs.
  • Focus and specialization are critical in the cell therapy space and we believe the combined company has the technologies necessary to succeed.
  • The combined company has a team of leading cell therapy experts led by Adrian Rawcliffe, the CEO of Adaptimmune.

Elbit Systems Awarded a $120 Million Follow-on Contract to Supply Unmanned Turrets, Weapon Stations and Mortar Systems to the Romanian Armed Forces

Retrieved on: 
Thursday, March 2, 2023

Under the follow-on contract, Elbit Systems will supply UT30 MK2 turrets, RCWS and the SPEAR mortar systems, all fully integrated onboard the GDELS' 'Piranha V' APC.

Key Points: 
  • Under the follow-on contract, Elbit Systems will supply UT30 MK2 turrets, RCWS and the SPEAR mortar systems, all fully integrated onboard the GDELS' 'Piranha V' APC.
  • Elbit Systems' UT30 MK2 is a 30mm unmanned light turret that integrates weapon systems, fire control systems, sensors and display systems for enhanced combat effectiveness, situational awareness and target acquisition capabilities.
  • In addition to Romania, Elbit Systems' turrets, RCWS and mortar systems have been selected to date by dozens of customers across the world including Israel, U.S.A, Denmark, Austria, Belgium, Brazil, and Croatia.
  • Bezhalel (Butzi) Machlis, Elbit Systems President & CEO: "This follow-on contract award is yet another vote of confidence in Elbit Systems' portfolio of solutions for armoured platforms.

Braskem drives its digital transformation

Retrieved on: 
Friday, December 2, 2022

SÃO PAULO, Dec. 2, 2022 /PRNewswire/ -- Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), the market leader and pioneer in the production of biopolymers on an industrial scale, has been investing regularly in new technologies and digital innovation for more than five years. The move is crucial to further consolidating the company's leadership position in the chemical industry, leveraging its innovative and competitive edge to generate sustainable impact and results.

Key Points: 
  • Braskem has been increasingly investing in digital technologies to boost competitiveness and productivity, drive growth across existing businesses, and accelerate gains in innovation and sustainability.
  • Since 2018, when the company's digital transformation began, Braskem has been making direct investments in technology.
  • An integral part of this digital transformation process has been promoting agile working methods and acquiring skills associated with developing digital solutions.
  • The initiative will foster disruptive innovations through different mechanisms for interacting with startups, always focusing on sustainability and digital transformation.

Immunoassay Technology Developer Spear Bio Presents Its NAB-SureTM SARS-CoV2 Neutralizing Antibody Test Kit at the American Association of Clinical Chemistry's Annual Event

Retrieved on: 
Friday, September 2, 2022

WOBURN, Mass., Sept. 2, 2022 /PRNewswire/ -- Developer of an ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its breakthrough immunoassay technology at the recent American Association of Clinical Chemistry's scientific meeting and clinical lab expo, held in Chicago.  

Key Points: 
  • At the AACC event Spear Bio unveiled its first product to market: the NAB-Sure SARS-CoV-2 neutralizing antibody (NAb) test kit.
  • Based on proprietary SPEAR technology, the NAB-Sure SARS-CoV-2 Assay is a powerful research tool in the fight against COVID-19 coronavirus disease.
  • It serves a variety of applications, including COVID-19 serosurveillance, vaccine efficacy testing, and longitudinal antibody durability testing.
  • The immunoassay test kit is capable of ultrasensitive protein detection for small sample sizes, such as dried blood spot (DBS) samples from a finger prick, which can be collected in-home.

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT

Retrieved on: 
Monday, May 16, 2022

PHILADELPHIA. and OXFORD, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell (ADP-A2M4N7X19) targeting MAGE-A4, and novel tumor-infiltrating lymphocytes (TILs) expressing IL-7 (ADP-TILIL7) at the American Society of Gene & Cell Therapy (ASGCT) annual meeting. The Company is presenting the two posters today at 5:30 p.m. EDT during the Cell Therapies I and Targeted Gene and Cell Therapy I sessions.

Key Points: 
  • The Company is presenting the two posters today at 5:30 p.m. EDT during the Cell Therapies I and Targeted Gene and Cell Therapy I sessions.
  • We have now presented preclinical data at ASGCT from our second next-gen therapy designed to improve durability and persistence of SPEAR T-cells that supports clinical investigation.
  • Adaptimmuneis a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer.
  • This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).

Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

Retrieved on: 
Wednesday, May 4, 2022

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.

Key Points: 
  • PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.
  • Jo Brewer is an exceptional scientific leader, and I am delighted that she has accepted the newly created CSO role, leading our ongoing scientific research, and developing future autologous and allogeneic therapies, said Adrian Rawcliffe, Adaptimmunes Chief Executive Officer.
  • She has played a crucial role in our collaborations with Astellas and Genentech.
  • Brewer served as Senior Vice President, Allogeneic Research at Adaptimmune since December 2019.

Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors

Retrieved on: 
Friday, April 8, 2022

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the multinational, multicenter, screening protocol (NCT02636855) at the American Association for Cancer Research (AACR) annual meeting in a poster entitled “Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell Therapies in HLA-A*02–Eligible Patients”.

Key Points: 
  • This information confirms the potential of our MAGE-A4 franchise and our continued commitment to patients and clinicians.
  • The screening protocol prospectively evaluated HLA types and MAGE-A4 expression levels to determine eligibility for the Companys clinical trials with SPEAR T-cells targeting MAGE-A4 across a broad range of solid tumors.
  • To be eligible, patients are required to be HLA-A*02 positive1 and tumor samples need to meet protocol-defined MAGE-A4 expression levels2 .
  • Data were collected for screening in the Phase 1 trial of afami-cel (formerly ADP-A2M4; closed to enrollment) as well as the ongoing Phase1 SURPASS trial.